Based on the dialogue with the FDA.

This review is normally on track, with a potential acceptance in Europe in the first quarter of 2011. The up to date corporate overview for ChemGenex is usually on the company’s website.. ChemGenex agrees with FDA on potential regulatory path to progress OMAPRO for CML ChemGenex Pharmaceuticals Small announced today it has agreed with the U.S. Based on the dialogue with the FDA, ChemGenex intends to combine data from its two pivotal research, Study 202 and Research 203, and post a New Drug Program for OMAPRO for those patients with CML who have failed prior treatment with two or more currently approved tyrosine kinase inhibitors . The proposed indication of the new NDA will become for the treating CML patients who’ve failed several TKIs, regardless of their mutation status. Related StoriesProtein-coding gene identified as tumor suppressor for severe myeloid leukemiaPenn study forms basis for new treatment methods for Sezary syndromeYK-4-279 compound functions against some types of leukemia: Study’The FDA’s agreement a combined data set could serve as the foundation of an NDA in a third-series setting provides us with a pathway to an expanded indication for OMAPRO to treat CML patients who are resistant to at least two TKIs,’ stated Adam Craig, MD, Chief Medical Officer of ChemGenex.About Sanofi Diabetes Sanofi strives to greatly help people manage the complex task of diabetes by delivering innovative, integrated and personalized solutions. Driven by precious insights which come from hearing and engaging with people living with diabetes, the Company can be forming partnerships to provide diagnostics, therapies, services, and gadgets including innovative blood sugar monitoring systems. Sanofi marketplaces both injectable and oral medications for those who have type 1 or type 2 diabetes.